We are live on
!
Find out more
DA
Dunvegan Associates Portfolio holdings
AUM
$85.1M
1-Year Est. Return
2.3%
This Fund
S&P 500
This Quarter
Est. Return
+3.98%
1 Year Est. Return
-2.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$119M
AUM Growth
-$2.39M
(-2%)
Cap. Flow
-$3.06M
Cap. Flow
% of AUM
-2.58%
Top 10 Holdings %
Top 10 Hldgs %
49.96%
Holding
224
New
153
Increased
5
Reduced
49
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$6.01M |
| 2 |
Cheniere Energy
LNG
|
+$918K |
| 3 |
Visa
V
|
+$252K |
| 4 |
CBI
Chicago Bridge & Iron Nv
CBI
|
+$172K |
| 5 |
Apple
AAPL
|
+$149K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.83M |
| 2 |
SPDR Gold Trust
GLD
|
+$1.84M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$1.27M |
| 4 |
GEB.CL
General Electric Capital Corp
GEB.CL
|
+$1.05M |
| 5 |
SCHW.PRB.CL
The Charles Schwab Corporation
SCHW.PRB.CL
|
+$755K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 20.26% |
| 2 | Financials | 13.68% |
| 3 | Healthcare | 11.87% |
| 4 | Consumer Staples | 10.96% |
| 5 | Materials | 6.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
State Street SPDR S&P Pharmaceuticals ETF
XPH
$491M
| $92K | 0.08% |
+1,974
| New | +$93.2K |
|
77
Banco Santander
SAN
$206B
| $89K | 0.07% |
+10,207
| New | +$83.4K |
|
78
Amazon
AMZN
$3.06T
| $87K | 0.07% |
+5,180
| New | +$96.1K |
|
79
Medtronic
MDT
$111B
| $74K | 0.06% |
+1,210
| New | +$70.5K |
|
80
iShares MSCI Chile ETF
ECH
$1.03B
| $73K | 0.06% |
+1,610
| New | +$69.9K |
|
81
Elevance Health
ELV
$83B
| $73K | 0.06% |
+735
| New | +$66.5K |
|
82
Merck
MRK
$316B
| $72K | 0.06% |
+1,326
| New | +$68.7K |
|
83
Vanguard FTSE Emerging Markets ETF
VWO
$121B
| $72K | 0.06% |
+1,783
| New | +$69.2K |
|
84
Walt Disney
DIS
$170B
| $71K | 0.06% |
+885
| New | +$68.6K |
|
85
Parker-Hannifin
PH
$126B
| $71K | 0.06% |
+590
| New | +$70.8K |
|
86
Enterprise Products Partners
EPD
$81.9B
| $69K | 0.06% |
+2,000
| New | +$66.3K |
|
87
Humana
HUM
$45B
| $64K | 0.05% |
+570
| New | +$59.4K |
|
88
iShares MSCI Mexico ETF
EWW
$1.97B
| $63K | 0.05% |
+984
| New | +$61.7K |
|
89
FedEx
FDX
$73.2B
| $61K | 0.05% |
+459
| New | +$62.3K |
|
90
Johnson & Johnson
JNJ
$613B
| $61K | 0.05% |
+618
| New | +$57.3K |
|
91
Suncor Energy
SU
$77.9B
| $61K | 0.05% |
+1,758
| New | +$58.6K |
|
92
Timken Company
TKR
$9.85B
| $60K | 0.05% |
+1,425
| New | +$58.6K |
|
93
VanEck Agribusiness ETF
MOO
$968M
| $59K | 0.05% |
+1,092
| New | +$57.6K |
|
94
Canadian Natural Resources
CNQ
$96.7B
| $58K | 0.05% |
+3,107
| New | +$52.5K |
|
95
Trane Technologies
TT
$101B
| $57K | 0.05% |
+1,000
| New | +$59.6K |
|
96
Vanguard FTSE Developed Markets ETF
VEA
$230B
| $55K | 0.05% |
+1,342
| New | +$55K |
|
97
Douglas Emmett
DEI
$1.99B
| $54K | 0.05% |
+2,000
| New | +$51.8K |
|
|
ACC
98
DELISTED
American Campus Communities, Inc.
ACC
| $54K | 0.05% |
+1,450
| New | +$51.4K |
|
|
SI
99
DELISTED
SIEMENS AKTIENGESELLSCHAFT ADS
SI
| $52K | 0.04% |
+386
| New | +$50.7K |
|
100
Colgate-Palmolive
CL
$71.9B
| $49K | 0.04% |
+762
| New | +$48K |
|
Similar funds
TSBJ
VCAM
KCA
TP
SPC
ST
CGC
GCG
Dunvegan Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Dunvegan Associates held 224 positions worth $119M, down 2% from $121M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Dunvegan Associates's Q1 2014 filing shows 153 new, 5 increased, 49 reduced and 8 closed positions. Its largest new stake was Allergan plc: 30,358 shares worth $3.77M. The largest sale was Allergan Inc, an estimated $3.83M.
By sector, the portfolio is most concentrated in Energy at 20% of assets, up from 18% a quarter earlier, followed by Financials and Healthcare.
- Dunvegan Associates's largest Q1 2014 buy was Allergan plc: 30,358 shares worth $3.77M.
- Dunvegan Associates added most to Cheniere Energy in Q1 2014, an estimated $918K increase.
- Dunvegan Associates's biggest Q1 2014 reduction was SPDR Gold Trust, cutting an estimated $1.84M.
- Dunvegan Associates fully exited Allergan Inc in Q1 2014, selling an estimated $3.83M.
- Dunvegan Associates's ten largest holdings make up 50% of its $119M portfolio in Q1 2014.
- Dunvegan Associates opened 153 new positions and closed 8 in Q1 2014.
- Dunvegan Associates's portfolio value fell 2% quarter-over-quarter to $119M.
Based on Dunvegan Associates's 13F filing for Q1 2014, filed 28 Apr 2017.